
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Barcelona - Promising advances have been in the development of prophylactic vaccines targeting human papillomavirus (HPV), the major cause of cervical cancer and a possible contributing factor in non-melanoma skin cancers, according to Reinhard Kirnbauer, M.D., Associate Professor of Dermatology at the University of Vienna Medical School in Austria.